Wordt geladen...
Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta‐Analysis of More Than 20 000 Patients
BACKGROUND: The monoclonal antibody bevacizumab effectively inhibits angiogenesis in several types of cancers by blocking vascular endothelial growth factor. However, life‐threatening cardiovascular adverse effects could limit its use and may warrant specific follow‐up strategies. METHODS AND RESULT...
Bewaard in:
| Gepubliceerd in: | J Am Heart Assoc |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5586462/ https://ncbi.nlm.nih.gov/pubmed/28862931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.117.006278 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|